Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Are 19del and L858R really different disease entities?

Future oncology (London, England) - 1 Jan 2024

Kim Seoree, Heo Yunseok, Lee Young-Ho, Kang Jin Hyoung

Abstract excerpt

Clinicians have recognized the similarities and differences between the two subtypes of common epidermal growth factor receptor (EGFR) mutations, but actual treatment strategies have not yet changed. The L858R mutation can be understood by considering the pharmacological conformational plasticity of the receptor protein and the presence of other co-occurring mutations, whether subtypes of EGFR or non-EGFR...

Topics

Humans
ErbB Receptors
Mutation
Neoplasms
Signal Transduction
Protein Kinase Inhibitors

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 39279671
DOI: 10.1080/14796694.2024.2362613
PMCID: PMC11486137

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Are 19del and L858R really different disease entities?PMID 39279671Read ↗

EGFR mutations and EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

Response to Erlotinib in a Patient with Compound EGFR L747S and Exon 19 Deletion.Semantic proximity Read ↗

Concomitant Mutations in EGFR 19Del/L858R Mutation and Their Association with Response to EGFR-TKIs in NSCLC PatientsSemantic proximity Read ↗

INTERESTing biomarker to select IDEAL patients for epidermal growth factor receptor tyrosine kinase inhibitors: yes, for EGFR mutation analysis, others, I PASS.Semantic proximity Read ↗

EGFR L858R mutation may go undetected because of P848L in cis mutation.Semantic proximity Read ↗

Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy.Semantic proximity Read ↗

An uncommon insertion mutation in exon 19 of EGFR showed stable disease after TKI treatment.Semantic proximity Read ↗

Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors.Semantic proximity Read ↗

[Differences between EGFR Exon 19 Deletion and Exon 21 L858R Point Mutation, Frequently Detected EGFR Mutations in Patients with Non-Small Cell Lung Cancer, from a Molecular Biology Viewpoint].Semantic proximity Read ↗

All EGFR mutations are (not) created equal: focus on uncommon EGFR mutations.Semantic proximity Read ↗

First case of A859T epidermal growth factor receptor mutation responding to erlotinib.Semantic proximity Read ↗

Rare EGFR exon 20 S768I mutation predicts resistance to targeted therapy: a report of two cases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.